Press Release


AIM Vaccine Announces Global Offering Results, Offer Price of HK$16.16 per H Share
Oct 05, 2022 18:55 JST
AIM Vaccine Co., Ltd. ("AIM Vaccine" or the "Company", together with its subsidiaries, the "Group", stock code: 06660.HK), the second largest vaccine company in China in terms of 2021 approved lot release volume (excluding COVID-19 vaccines)
More info..

AIM Vaccine Announces Proposed Listing on the Main Board of SEHK
Sep 23, 2022 17:06 JST
AIM Vaccine Co., Ltd. ("AIM Vaccine"; 06660.HK), the second largest vaccine company in China in terms of 2021 approved lot release volume (excluding COVID-19 vaccines), announced the proposed listing of its H shares on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK") today.
More info..

Phase I Clinical Trial of AIM mRNA COVID-19 Vaccine (LVRNA009) Won the Praise of the Industry for High Safety and Well Tolerance
Jan 12, 2022 10:26 JST
On January 8, AIM Vaccine held a meeting at Shulan (Hangzhou) Hospital to report on the analysis results of the phase I clinical trial data of its mRNA COVID-19 vaccine (LVRNA009).
More info..

Latest Release


More Latest Release >>